Why AstraZeneca’s Tagrisso keeps raising the bar in lung cancer care

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-20, 05:15. Details in the imprint.

With Tagrisso, AstraZeneca brings a quiet but uncompromising tablet into oncology wards that has changed everyday routine for many lung cancer teams. The small, film-coated pill targets tumors with EGFR mutations and, in many cases, keeps them in check for noticeably longer.

What Tagrisso is approved to do

Tagrisso (active ingredient osimertinib) is designed for adults with non-small cell lung cancer whose tumors carry specific EGFR mutations, including the resistance mutation T790M, which often appears after first-line treatment. It is taken orally once daily as a targeted therapy instead of classic chemotherapy.

The medicine is approved in the EU, US and many other markets both for advanced, metastatic EGFR-mutated disease and, more recently, for adjuvant use after surgical removal of the tumor in certain patients. In practice, that means it is used in both the chronic, metastatic setting and earlier-stage disease.

Data that changed daily routine

For oncologists, the real shift came with the large FLAURA and ADAURA studies, in which Tagrisso significantly prolonged progression-free survival compared with older EGFR inhibitors or placebo. In the ADAURA adjuvant trial, the tablet reduced the risk of death in resected EGFR-mutated lung cancer by a convincing margin.

This translates into fewer visible relapses on CT scans and longer intervals in which patients report feeling stable enough to work, spend time with family, or simply plan ahead. Doctors describe it as a comparatively tidy therapy schedule, with regular monitoring but no infusion days.

How the therapy feels in practice

From the patient’s perspective, Tagrisso often means a daily rhythm: swallow the tablet, deal with manageable side effects like rash or diarrhea, and otherwise try to live as normally as possible. Some report dry skin and brittle nails as constant companions, others fatigue that creeps in quietly.

Compared with platinum-based chemotherapy, there is usually no hair loss and fewer acute nausea episodes, which many find relieving. Yet this is not a gentle wellness pill - cardiovascular and lung side effects are monitored carefully, and regular ECGs and blood tests are standard in many clinics.

Where Tagrisso stands versus rivals

In EGFR-mutated lung cancer, Tagrisso competes with a growing line-up of TKIs from Japan, South Korea and China, some of them cheaper generics or regionally developed alternatives. Still, leading guidelines in Europe and the US continue to list it as a preferred first-line option in many EGFR-mutated settings.

The drug’s ability to penetrate the central nervous system is a practical advantage, because brain metastases are common in this tumor type. Neuroradiologists often see fewer new CNS lesions under treatment than they did with earlier EGFR inhibitors, according to published follow-up data.

Pricing, access, and everyday economics

Tagrisso is a high-price specialty drug and usually dispensed via hospital or specialty pharmacies. Exact list prices vary by country and are subject to confidential discount agreements, but in major markets it clearly sits in the premium oncology segment.

For health systems, that means tough budget discussions, especially as more patients receive Tagrisso earlier in the disease course and for longer periods. Payers often demand strong overall-survival data and real-world evidence, which AstraZeneca is actively collecting and publishing in phases.

Why the product matters for AstraZeneca

Tagrisso has grown into one of AstraZeneca’s top-selling oncology brands, alongside immunotherapies such as Imfinzi. In the company’s recent results, lung cancer therapies again contributed a substantial share of oncology revenue, underlining how central this segment remains for the pipeline.

All told, Tagrisso illustrates the group’s clear strategic push into biomarker-driven cancer medicine, where companion diagnostics, targeted tablets and combination regimens interlock tightly with clinical guidelines and payer expectations.

Company angle and stock reference

For AstraZeneca, Tagrisso is more than a single product - it anchors a broader franchise in thoracic oncology, with studies exploring combinations and earlier use in high-risk patients. Shares of AstraZeneca plc (GB0009895292) are listed on the London Stock Exchange and on Nasdaq in New York via ADRs.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.